



Health by Advanced Therapies

---

D 1.5  
Defining key performance parameters for the candidate  
LSRI RESTORE  
Public

---

Delivery date: 29/02/2020

Lead Beneficiary: Name (Charité)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 820292.

[www.restore-horizon.eu](http://www.restore-horizon.eu)



## Table of contents

1. Deliverable's description .....	3
2. Key Performance Indicators .....	4

## 1. Deliverable's description

This deliverable aims to outline some key performance indicators to monitor the progress of the candidate large-scale research initiative, RESTORE.

## 2. Key Performance Indicators

Without clear approval of the future of large-scale research initiative (LSRI) RESTORE, it is currently difficult to define Key Performance Indicators.

Assuming that there will be a LSRI RESTORE based on our concept in the Horizon-Europe programme, we propose the following set of performance indicators:

Overarching level:

- Number of academic hubs approved/certified for translational research on Advanced Therapies and interlinked to a network measurable by joint translational projects, clinical studies, and therapeutic applications
- Number of key technologies developed within the LSRI RESTORE that will be applied in European and non-European countries for research and clinical routine
- Number of early and late clinical trials on new Advanced Therapies
- Number of Advanced Therapy products that receive marketing authorization and become accessible to patients
- Number of filed and granted patents (IP portfolio generation)
- Level of mobilization of additional public and preferentially private money invested in Europe into the Advanced Therapy field
- Commercial success rate with ATMP/bio-MD and intermediate products (e.g. novel preclinical organ-on-chip models) measurable by increased revenues from industry (return of investment)
- Number of patients treated by Advanced Therapy products with sustainable success or even cure
- Active involvement of patients and their representatives in project selection and clinical trial design
- Increased knowledge about Advanced Therapies in the public society
- Number of scientists and physicians who moved into the research field of ATMP/bio-MD recruited from European and non-European countries

By regularly evaluating this key set of parameters, we can facilitate optimal decision-making and allocation of resources to ensure the progress of RESTORE.